Compositions Comprising Soluble HLA/M. Tuberculosis-Specific Ligand Complexes and Methods of Production and Use Thereof

摘要

Compositions that include at least one isolated, class I HLA trimolecular complex that includes a peptide ligand unique to M. tuberculosis-infected cells are disclosed. Isolated compositions that include the three components of the trimolecular complex and/or a polynucleotide encoding one or more of the three components are also disclosed.

主权项

1. A composition, comprising at least one of:
(a) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:1, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (b) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:2 and/or 3, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (c) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:4, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (d) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:5, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (e) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising at least one of SEQ ID NOS:6-9, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (f) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:10 and/or 11, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (g) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:12 and/or 13, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (h) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:14, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (i) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:15, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (j) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:16, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (k) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising at least one of SEQ ID NOS:17-20, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (l) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:21, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (m) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:22, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (n) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:23 and/or 24, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (o) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:25 and/or 26, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (p) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:27, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; (q) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:28, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain; and (r) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:29, and wherein the soluble, truncated HLA-E heavy chain does not contain the transmembrane and cytoplasmic domains of the native, full length HLA-E heavy chain.